Single User License
INR 101235
Site License
INR 202470
Corporate User License
INR 303705

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Otsuka Holdings Co., Ltd.-Product Pipeline Review-2015

Otsuka Holdings Co., Ltd.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Otsuka Holdings Co., Ltd.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Otsuka Holdings Co., Ltd.-Product Pipeline Review-2015', provides an overview of the Otsuka Holdings Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Otsuka Holdings Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Otsuka Holdings Co., Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Otsuka Holdings Co., Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Otsuka Holdings Co., Ltd.'s pipeline products

Reasons To Buy

Evaluate Otsuka Holdings Co., Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Otsuka Holdings Co., Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Otsuka Holdings Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Otsuka Holdings Co., Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Otsuka Holdings Co., Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Otsuka Holdings Co., Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Otsuka Holdings Co., Ltd. Snapshot 7

Otsuka Holdings Co., Ltd. Overview 7

Key Information 7

Key Facts 7

Otsuka Holdings Co., Ltd.-Research and Development Overview 8

Key Therapeutic Areas 8

Otsuka Holdings Co., Ltd.-Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products-Monotherapy 13

Pipeline Products-Combination Treatment Modalities 14

Pipeline Products-Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Otsuka Holdings Co., Ltd.-Pipeline Products Glance 17

Otsuka Holdings Co., Ltd.-Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Phase III Products/Combination Treatment Modalities 18

Otsuka Holdings Co., Ltd.-Clinical Stage Pipeline Products 19

Phase II Products/Combination Treatment Modalities 19

Phase I Products/Combination Treatment Modalities 20

Otsuka Holdings Co., Ltd.-Drug Profiles 21

(tipiracil hydrochloride + trifluridine) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

aripiprazole 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

brexpiprazole 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

tolvaptan 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

trabectedin 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

(aripiprazole + sertraline) 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

(carteolol hydrochloride + latanoprost) 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

delamanid 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

nabiximols 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

rebamipide 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

(dextromethorphan hydrobromide + quinidine sulfate) 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

AVP-786 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

OCV-101 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

OCV-501 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

OPA-15406 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

probucol 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

tetomilast 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

OPA-6566 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

OPB-111001 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

OPB-31121 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

LPC-01 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

OCVC-02 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

OPB-111077 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

OPB-51602 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

OPC-108459 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

OPS-2071 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Otsuka Holdings Co., Ltd.-Pipeline Analysis 61

Otsuka Holdings Co., Ltd.-Pipeline Products by Target 61

Otsuka Holdings Co., Ltd.-Pipeline Products by Route of Administration 63

Otsuka Holdings Co., Ltd.-Pipeline Products by Molecule Type 64

Otsuka Holdings Co., Ltd.-Pipeline Products by Mechanism of Action 65

Otsuka Holdings Co., Ltd.-Recent Pipeline Updates 67

Otsuka Holdings Co., Ltd.-Dormant Projects 88

Otsuka Holdings Co., Ltd.-Discontinued Pipeline Products 89

Discontinued Pipeline Product Profiles 89

(tipiracil hydrochloride + trifluridine) 89

AVP-13358 89

AZD-2479 89

rebamipide 89

Otsuka Holdings Co., Ltd.-Company Statement 90

Otsuka Holdings Co., Ltd.-Locations And Subsidiaries 91

Head Office 91

Other Locations & Subsidiaries 91

Appendix 97

Methodology 97

Coverage 97

Secondary Research 97

Primary Research 97

Expert Panel Validation 97

Contact Us 97

Disclaimer 98

List of Tables

Otsuka Holdings Co., Ltd., Key Information 7

Otsuka Holdings Co., Ltd., Key Facts 7

Otsuka Holdings Co., Ltd.-Pipeline by Indication, 2015 9

Otsuka Holdings Co., Ltd.-Pipeline by Stage of Development, 2015 12

Otsuka Holdings Co., Ltd.-Monotherapy Products in Pipeline, 2015 13

Otsuka Holdings Co., Ltd.-Combination Treatment Modalities in Pipeline, 2015 14

Otsuka Holdings Co., Ltd.-Partnered Products in Pipeline, 2015 15

Otsuka Holdings Co., Ltd.-Partnered Products/ Combination Treatment Modalities, 2015 16

Otsuka Holdings Co., Ltd.-Pre-Registration, 2015 17

Otsuka Holdings Co., Ltd.-Phase III, 2015 18

Otsuka Holdings Co., Ltd.-Phase II, 2015 19

Otsuka Holdings Co., Ltd.-Phase I, 2015 20

Otsuka Holdings Co., Ltd.-Pipeline by Target, 2015 62

Otsuka Holdings Co., Ltd.-Pipeline by Route of Administration, 2015 63

Otsuka Holdings Co., Ltd.-Pipeline by Molecule Type, 2015 64

Otsuka Holdings Co., Ltd.-Pipeline Products by Mechanism of Action, 2015 66

Otsuka Holdings Co., Ltd.-Recent Pipeline Updates, 2015 67

Otsuka Holdings Co., Ltd.-Dormant Developmental Projects,2015 88

Otsuka Holdings Co., Ltd.-Discontinued Pipeline Products, 2015 89

Otsuka Holdings Co., Ltd., Other Locations 91

Otsuka Holdings Co., Ltd., Subsidiaries 91

List of Figures

Otsuka Holdings Co., Ltd.-Pipeline by Top 10 Indication, 2015 9

Otsuka Holdings Co., Ltd.-Pipeline by Stage of Development, 2015 12

Otsuka Holdings Co., Ltd.-Monotherapy Products in Pipeline, 2015 13

Otsuka Holdings Co., Ltd.-Combination Treatment Modalities in Pipeline, 2015 14

Otsuka Holdings Co., Ltd.-Partnered Products in Pipeline, 2015 15

Otsuka Holdings Co., Ltd.-Pipeline by Top 10 Target, 2015 61

Otsuka Holdings Co., Ltd.-Pipeline by Top 10 Route of Administration, 2015 63

Otsuka Holdings Co., Ltd.-Pipeline by Top 10 Molecule Type, 2015 64

Otsuka Holdings Co., Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 65

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Otsuka Holdings Co., Ltd.; Otsuka Holdings Co., Ltd. - Key Therapeutics; Otsuka Holdings Co., Ltd. - Pipeline Overview and Promising Molecules; Otsuka Holdings Co., Ltd. - News; Otsuka Holdings Co., Ltd. - Latest Updates; Otsuka Holdings Co., Ltd. - Pipeline; Otsuka Holdings Co., Ltd. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com